QL1706 (Iparomlimab/Tuvonralimab): A Comprehensive Analysis of a Novel Bifunctional PD-1/CTLA-4 MabPair Immunotherapy

Executive Summary

QL1706 is a first-in-class, investigational bifunctional antibody product developed by Qilu Pharmaceutical Co., Ltd., representing a significant innovation in the field of cancer immunotherapy. Identified by the DrugBank ID DB17562 and the development code PSB205, QL1706 is not a single bispecific antibody but rather a co-formulated mixture of two distinct monoclonal antibodies: Tuvonralimab, an anti-Programmed Death-1 (PD-1) IgG4 antibody, and Iparomlimab, an anti-Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) IgG1 antibody. This unique composition is achieved through the proprietary MabPair™ technology platform, which enables the production of both antibodies from a single cell line at a fixed ratio, ensuring consistent delivery and synergistic action.

The core therapeutic rationale of QL1706 is to harness the proven synergistic anti-tumor efficacy of dual PD-1 and CTLA-4 blockade while mitigating the significant immune-related toxicities that have limited the use of conventional combination therapies. This is achieved through sophisticated bioengineering of the Iparomlimab (anti-CTLA-4) component to possess a shorter elimination half-life compared to the Tuvonralimab (anti-PD-1) component. This design provides a potent initial "pulse" of CTLA-4 inhibition to prime a broad T-cell response, followed by sustained PD-1 inhibition to maintain the activity of these T-cells within the tumor microenvironment, thereby uncoupling efficacy from cumulative toxicity.

The extensive clinical development program for QL1706 has demonstrated promising efficacy and a manageable safety profile across a range of solid tumors. In recurrent or metastatic cervical cancer, the drug has shown robust activity both as a monotherapy in later lines and in combination with chemotherapy in the first-line setting, leading to its accelerated approval by China's National Medical Products Administration (NMPA). In non-small cell lung cancer (NSCLC), QL1706 has delivered compelling response rates and progression-free survival benefits in both epidermal growth factor receptor (EGFR) wild-type and treatment-resistant EGFR-mutant populations. Furthermore, a pivotal study in advanced hepatocellular carcinoma (aHCC) provided direct clinical evidence of the anti-CTLA-4 component's significant contribution to overall efficacy.

The safety profile of QL1706 appears favorable, with a notably low rate of severe immune-related adverse events in large-scale monotherapy studies, supporting its core design hypothesis. The ongoing portfolio of Phase III trials, including head-to-head comparisons against existing standards of care in challenging patient populations such as PD-L1-negative NSCLC, will be critical in defining its ultimate position in the therapeutic armamentarium. Contingent on the outcomes of these pivotal studies, QL1706 is poised to become a significant, potentially best-in-class, dual checkpoint inhibitor, offering a new standard of care with an improved therapeutic index for patients with a variety of advanced malignancies.

Introduction to QL1706 and the MabPair Technology Platform

The landscape of oncology has been reshaped by the advent of immune checkpoint inhibitors, which restore the immune system's ability to recognize and eliminate cancer cells. The development of agents targeting PD-1 and CTLA-4 has established a new pillar of cancer treatment. Within this evolving field, QL1706 emerges as a highly differentiated, next-generation therapeutic designed to optimize the balance between efficacy and safety in dual checkpoint blockade.

Drug Identification and Development

QL1706 is an investigational biotech drug, cataloged in DrugBank under the identifier DB17562 and also known by its development code, PSB205.[1] The product is a combination of two distinct humanized monoclonal antibodies: Iparomlimab, which targets CTLA-4, and Tuvonralimab, which targets PD-1.[3] The agent is being developed by Qilu Pharmaceutical Co., Ltd., a prominent vertically integrated pharmaceutical company based in China, which is spearheading its extensive clinical trial program.[5] The underlying technology and initial development were pioneered by Sound Biologics.[14]

The MabPair Technology Platform

QL1706 is the first therapeutic agent to be developed using the proprietary and innovative MabPair™ technology platform.[14] This platform represents a novel approach to combination antibody therapy. It involves the genetic engineering of a single, stable mammalian cell line to co-express two different monoclonal antibodies. This process is meticulously controlled to ensure that the two antibodies are produced at a consistent, predetermined ratio—approximately 2:1 for the anti-PD-1 (Tuvonralimab) and anti-CTLA-4 (Iparomlimab) components of QL1706.[16] The resulting drug substance is a mixture of these two distinct antibodies, which is then purified, formulated, and manufactured as a single, final drug product.[17]

Strategic Rationale and Differentiation

The selection of the MabPair platform is a deliberate strategic decision that positions QL1706 apart from other approaches to dual checkpoint inhibition. This technology was chosen to overcome the inherent limitations of both simple drug combinations and single-molecule bispecific antibodies.

Conventional combination therapy, such as the co-administration of nivolumab (anti-PD-1) and ipilimumab (anti-CTLA-4), has proven effective but is often associated with significant toxicity and requires complex dosing regimens to manage adverse events.[22] It also presents logistical challenges related to the supply chain, pharmacy preparation, and administration of two separate products.

On the other hand, single-molecule bispecific antibodies, which contain two different antigen-binding sites on one molecule, can offer convenience but come with their own set of challenges. The fixed architecture of a bispecific antibody may lead to suboptimal binding, potential steric hindrance between the binding domains, and complex manufacturing and purification processes. Crucially, both antigen-targeting components of a single bispecific molecule are inherently linked to the same pharmacokinetic (PK) profile, preventing the independent modulation of exposure for each target.

The MabPair platform offers a sophisticated solution that captures the advantages of both approaches while mitigating their respective drawbacks. It provides the clinical and manufacturing convenience of a single-vial product, similar to a bispecific antibody. However, because it is a mixture of two separate antibodies, each component can be independently engineered and optimized for its specific biological purpose. This includes the selection of the ideal Immunoglobulin G (IgG) subclass and the modification of the antibody structure to fine-tune its half-life and effector functions—a level of customization not achievable with a single bispecific molecule.[14]

This capacity for independent engineering is exemplified in the design of QL1706. The anti-PD-1 component, Tuvonralimab, is an IgG4 monoclonal antibody, while the anti-CTLA-4 component, Iparomlimab, is an IgG1 monoclonal antibody.[6] This choice of IgG subclasses is immunologically significant. The IgG4 isotype has very low effector function, meaning it is less likely to trigger Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) or Complement-Dependent Cytotoxicity (CDC). This is advantageous for an anti-PD-1 antibody, as its primary role is to block the PD-1 receptor and "release the brakes" on T-cells without inadvertently causing their destruction.[25] In contrast, the IgG1 isotype possesses potent effector functions. This is beneficial for an anti-CTLA-4 antibody, as one of its key mechanisms is thought to be the depletion of highly immunosuppressive regulatory T-cells (Tregs), which express high levels of CTLA-4, within the tumor microenvironment. The ability to mediate ADCC via the IgG1 backbone can enhance this depletion, further augmenting the anti-tumor immune response. This nuanced molecular design, enabled by the MabPair platform, reflects a sophisticated strategy to tailor the biological activity of each antibody to its specific role, thereby maximizing the therapeutic potential of the combination.

Scientific Foundation and Mechanism of Action

The scientific premise of QL1706 is rooted in the synergistic activity of simultaneously blocking two of the most well-validated inhibitory checkpoints in cancer immunology: PD-1 and CTLA-4. The novelty of QL1706 lies not in the choice of targets, but in its engineered design to optimize the clinical benefit of this dual blockade.

Rationale for Dual PD-1 and CTLA-4 Blockade

CTLA-4 and PD-1 are non-redundant negative regulators of T-cell activation that function at different stages and locations of the immune response. CTLA-4 primarily acts as a master regulator during the initial T-cell priming phase. It is upregulated on T-cells following their activation in secondary lymphoid organs, such as lymph nodes. There, it outcompetes the co-stimulatory molecule CD28 for binding to its ligands (CD80 and CD86) on antigen-presenting cells, effectively dampening the initial activation signal and limiting the proliferation of newly activated T-cells. Inhibition of CTLA-4 therefore "takes the brakes off" at this early stage, leading to a broader and more robust T-cell activation and proliferation, and increasing the diversity of the anti-tumor T-cell repertoire.[20]

In contrast, the PD-1 pathway primarily functions at a later stage, within the tumor microenvironment. PD-1 is expressed on activated T-cells that have infiltrated the tumor. Its ligand, PD-L1, is often upregulated on the surface of tumor cells and other cells within the tumor microenvironment in response to inflammatory signals like interferon-gamma. The binding of PD-1 to PD-L1 delivers an inhibitory signal that leads to T-cell anergy, exhaustion, and apoptosis, effectively shutting down the anti-tumor immune attack at the site of the disease. Inhibition of the PD-1/PD-L1 axis restores the function of these exhausted, tumor-infiltrating T-cells, allowing them to resume their cytotoxic activity against cancer cells.[28]

Because these pathways are distinct, their combined inhibition is highly synergistic. CTLA-4 blockade broadens the pool of tumor-reactive T-cells, while PD-1 blockade ensures that these T-cells can remain functional and effective once they reach the tumor. This dual approach has demonstrated superior clinical efficacy compared to monotherapy with either agent alone and has led to regulatory approvals for the combination of nivolumab and ipilimumab in several cancers, including melanoma, renal cell carcinoma, and NSCLC.[18]

Engineered Pharmacokinetics for an Improved Therapeutic Index

While the efficacy of dual PD-1/CTLA-4 blockade is well-established, its clinical utility has been hampered by a high incidence of severe and sometimes life-threatening immune-related adverse events (irAEs). Clinical experience has shown that the toxicity profile, particularly the rate of severe irAEs, is more closely associated with the dose and exposure of the anti-CTLA-4 antibody (ipilimumab) than the anti-PD-1 antibody.[22]

QL1706 was specifically designed to address this fundamental challenge. The central innovation is the molecular engineering of the anti-CTLA-4 component, Iparomlimab, to have a significantly shorter elimination half-life (t1/2​) than the anti-PD-1 component, Tuvonralimab. Clinical pharmacokinetic data have confirmed the success of this design, showing that Iparomlimab has a half-life of approximately 4–5 days, while Tuvonralimab has a more conventional antibody half-life of 6–9 days.[14] This differential PK profile is the cornerstone of the drug's therapeutic hypothesis.

The "Pulse and Sustain" Therapeutic Hypothesis

The engineered differential pharmacokinetics of QL1706 gives rise to a novel immunomodulatory strategy that can be described as "pulse and sustain." Upon administration, the drug delivers a high initial exposure of both antibodies. The potent, initial "pulse" of CTLA-4 blockade is hypothesized to be sufficient to effectively prime the immune system, expanding the population and diversity of anti-tumor T-cells. However, due to its rapid clearance, the systemic exposure to the anti-CTLA-4 antibody diminishes significantly over the dosing interval. This reduction in sustained exposure is intended to mitigate the cumulative, dose-dependent toxicities associated with persistent CTLA-4 inhibition.

Simultaneously, the anti-PD-1 component, with its longer half-life, provides "sustained" blockade of the PD-1 pathway throughout the dosing cycle. This ensures that the T-cells activated by the initial CTLA-4 pulse are protected from PD-L1-mediated exhaustion when they infiltrate the tumor microenvironment.

This temporal modulation of the immune response from a single, conveniently administered product represents a sophisticated attempt to uncouple the potent synergistic efficacy of dual blockade from its dose-limiting toxicity. The goal is to create a therapeutic with a substantially improved therapeutic index—that is, a wider margin between the dose required for efficacy and the dose that causes unacceptable toxicity—compared to conventional combinations. This strategy aims to deliver the full power of dual checkpoint inhibition with a more manageable and favorable safety profile, potentially allowing its use in a broader range of patients and clinical settings.

Preclinical Evidence and Rationale for Clinical Development

The advancement of QL1706 into human clinical trials was predicated on a robust preclinical program designed to validate both the efficacy of the dual-targeting concept and the safety benefits of the novel MabPair engineering approach. While granular details of specific experiments are not fully available in the provided documentation, multiple sources confirm the completion of a comprehensive preclinical data package that established the scientific foundation for clinical investigation.[25]

Preclinical Efficacy and Synergy

Preclinical studies conducted with PSB205 (the development code for QL1706) in various tumor models reportedly demonstrated superior anti-tumor efficacy when compared to treatment with either a single anti-PD-1 or a single anti-CTLA-4 antibody alone.[14] These findings were critical, as they provided the initial in vivo evidence that the co-formulated product could replicate the known synergistic activity of dual checkpoint blockade. The success in these preclinical models confirmed that the two antibody components could act in concert to produce a more potent anti-tumor effect than either agent individually, providing the primary rationale for pursuing this combination strategy in a clinical setting. Preliminary in vitro and in vivo factorial studies were conducted to analyze the properties of both antibodies before advancing the program.[32]

Validation of the Engineered Safety Profile

A central objective of the preclinical program was to test the core hypothesis that engineering the anti-CTLA-4 component for a shorter half-life would lead to a more favorable safety profile. The preclinical studies were designed to assess whether this approach could effectively reduce the known toxicities associated with sustained CTLA-4 blockade while preserving the robust anti-tumor activity of the combination.[14] The successful outcomes of these studies provided the necessary evidence that the MabPair design could indeed offer a better-tolerated alternative to existing dual checkpoint inhibitor combinations. This de-risking step was crucial, as the primary barrier to the widespread use of combined nivolumab and ipilimumab has been its challenging safety profile. The preclinical data suggesting that QL1706 could overcome this hurdle was a key factor in the decision to proceed with clinical development.

Foundation for Regulatory Engagement

The compelling preclinical data package, which demonstrated both synergistic efficacy and a potentially improved safety profile, formed the basis of the Investigational New Drug (IND) application submitted to regulatory authorities. In April 2019, the U.S. Food and Drug Administration (FDA) allowed the IND for PSB205, authorizing the initiation of the first-in-human Phase 1 clinical trial in the United States for patients with relapsed and refractory solid tumors.[33] This regulatory milestone marked the official transition of QL1706 from a preclinical concept to a clinical-stage asset, validating the strength of the scientific rationale and the quality of the supporting preclinical evidence.

Comprehensive Clinical Development Program

The clinical development of QL1706 has been extensive and ambitious, reflecting a strong commitment from its developers to establish its role across a wide spectrum of solid tumors. The program has progressed rapidly from initial first-in-human studies to a broad portfolio of late-stage, pivotal trials. The overarching strategy appears to involve establishing a foundational safety and efficacy profile in a broad Phase 1/1b study, followed by a multi-pronged approach of launching registrational trials in high-priority indications while simultaneously exploring activity in other tumor types with significant unmet need. This comprehensive program is designed to fully elucidate the therapeutic potential of the novel MabPair platform.

The table below provides a consolidated overview of the key clinical trials that constitute the global development program for QL1706, compiled from numerous public records and scientific publications. This summary serves as a strategic map, illustrating the breadth of indications being pursued, the stage of development for each, and the specific therapeutic questions being addressed in each study.

Table 1: Summary of Key Clinical Trials for QL1706

NCT Identifier	Phase	Study Title/Brief Description	Condition(s)	Interventions	Status (as of latest snippet)	Source Snippet(s)
NCT04296994	1	First-in-human dose escalation and expansion study of QL1706 (PSB205)	Advanced Solid Tumors	QL1706	Completed/Results Published	2
NCT05171790	1b	Phase 1b trial of QL1706 (cervical cancer cohort reported)	Advanced Solid Tumors (incl. Cervical Cancer)	QL1706	Completed/Results Published	2
NCT05329025	2	DUBHE-L-201: QL1706 + chemo +/- bevacizumab in advanced NSCLC	Non-Small Cell Lung Cancer (NSCLC)	QL1706, Chemotherapy, Bevacizumab	Completed/Results Published	6
NCT05557565	2	DUBHE-C-206: Efficacy and safety of QL1706 in patients with cervical cancer	Cervical Cancer	QL1706	Completed/Results Published	1
NCT05603039	1b/2	QL1706 or QL1604 + bevacizumab as first-line treatment for aHCC	Advanced Hepatocellular Carcinoma (aHCC)	QL1706, QL1604, Bevacizumab	Active (data presented)	45
NCT05446883	3	QL1706 + Chemo +/- Bevacizumab for first-line persistent, recurrent or metastatic cervical cancer	Cervical Cancer	QL1706, Chemotherapy, Bevacizumab, Placebo	Recruiting	2
NCT05487391	3	QL1706 + Chemo vs. Placebo + Chemo as adjuvant therapy for Stage II-IIIB NSCLC	Non-Small Cell Lung Cancer (NSCLC)	QL1706, Chemotherapy, Placebo	Recruiting	2
NCT05690945	3	QL1706 + Chemo vs. Tislelizumab + Chemo in first-line PD-L1 negative advanced NSCLC	Non-Small Cell Lung Cancer (NSCLC)	QL1706, Tislelizumab, Chemotherapy	Recruiting	10
NCT06749899	3	QL1706 + Chemoradiotherapy vs. Chemoradiotherapy alone in LANPC	Locoregionally-Advanced Nasopharyngeal Carcinoma (LANPC)	QL1706, Chemotherapy, Radiotherapy	Recruiting	46
NCT07025239	3	QL1706 + Bevacizumab + XELOX vs. Placebo + Bevacizumab + XELOX in first-line mCRC	Metastatic Colorectal Cancer (mCRC)	QL1706, Bevacizumab, XELOX, Placebo	Not yet recruiting	9
NCT06786026	2	QL1706 + Nab-paclitaxel +/- Bevacizumab in first-line recurrent/metastatic TNBC	Triple-Negative Breast Cancer (TNBC)	QL1706, Nab-paclitaxel, Bevacizumab	Recruiting	47
NCT06967103	2	QL1706 + Chemo for neoadjuvant treatment of HR+/HER2- Breast Cancer	HR+/HER2- Breast Cancer	QL1706, Chemotherapy (Nab-PE)	Not yet recruiting	49
NCT07005583	2	QL1706 + Olaparib for previously treated HRD recurrent/metastatic TNBC	Triple-Negative Breast Cancer (TNBC)	QL1706, Olaparib	Not yet recruiting	48
NCT06917092	2	QL1706-based therapy post-PD-1/L1 failure in advanced endometrial cancer	Endometrial Adenocarcinomas	QL1706, Bevacizumab	Recruiting	51
NCT06766305	1	QL1706 + SOX for perioperative treatment of Gastric Cancer	Gastric Cancers	QL1706, SOX chemotherapy	Recruiting	50
NCT06809530	1	Intrathecal QL1706 + Pemetrexed for Leptomeningeal Metastasis	Leptomeningeal Metastasis	QL1706, Pemetrexed	Recruiting	63

Clinical Efficacy and Safety Analysis by Indication

The clinical utility of QL1706 has been evaluated across a diverse range of solid tumors, yielding a substantial body of evidence regarding its efficacy and safety. The following sections provide a detailed, indication-specific analysis of the key clinical findings to date, integrating data from peer-reviewed publications, major oncology conference presentations, and clinical trial registries.

Non-Small Cell Lung Cancer (NSCLC)

NSCLC represents a primary focus of the QL1706 development program, with data available from a pivotal Phase II study and multiple ongoing Phase III trials. The strategy in NSCLC has been to evaluate the agent in distinct, clinically relevant patient populations.

Phase II Study (NCT05329025 / DUBHE-L-201)

This open-label, multi-cohort Phase II study provided the first robust evidence of QL1706's efficacy in advanced NSCLC.[35] The trial was designed to assess the agent in combination with chemotherapy, with or without the anti-angiogenic agent bevacizumab, in two main populations: treatment-naïve patients with EGFR wild-type tumors and patients with EGFR-mutant tumors who had developed resistance to tyrosine kinase inhibitors (TKIs).

• EGFR Wild-Type Population (First-Line Treatment): In the cohorts of patients with EGFR wild-type NSCLC (n=60), the combination of QL1706 plus platinum-based chemotherapy demonstrated significant anti-tumor activity. In the combined analysis of these cohorts, the confirmed Objective Response Rate (ORR) was 45%, and the median Progression-Free Survival (mPFS) was 6.8 months (95% CI: 5.2–9.7). The Disease Control Rate (DCR), which includes patients with stable disease, was a notable 88.3%.[35] An earlier data cut from a subset of 29 patients, presented at the ESMO Asia Congress 2022, reported an even higher ORR of 58.6% and an mPFS of 6.97 months, highlighting the promising potential in this setting.[6] These results established QL1706 as a highly active agent in the first-line treatment of NSCLC, forming the basis for its advancement into Phase III trials.
• EGFR-Mutant, TKI-Resistant Population: This population represents a significant unmet medical need, as patients inevitably develop resistance to EGFR-TKIs. In Cohort 5 of the study, 31 patients with EGFR-mutant NSCLC who had progressed on prior TKI therapy received QL1706 in combination with chemotherapy (pemetrexed and carboplatin) and bevacizumab. This combination yielded an impressive ORR of 54.8% and an mPFS of 8.5 months.[35] Updated, long-term follow-up data presented more recently provided further evidence of durable benefit, with a median Duration of Response (mDoR) of 11.33 months, an mPFS of 8.51 months, and a remarkable median Overall Survival (mOS) of 26.51 months.[3] These findings are particularly compelling, suggesting that the addition of dual checkpoint blockade to an anti-angiogenic and chemotherapy backbone could be a highly effective strategy to overcome TKI resistance.

Phase III Clinical Program

Building on the strength of the Phase II data, Qilu Pharmaceutical has initiated a comprehensive Phase III program for QL1706 in NSCLC. This program includes two pivotal trials targeting distinct therapeutic settings:

• NCT05487391: This randomized, double-blind, placebo-controlled study is evaluating QL1706 in combination with platinum-based chemotherapy as an adjuvant (post-surgical) treatment for patients with completely resected Stage II-IIIB NSCLC.[2] Success in this trial could establish QL1706 as a new standard of care for preventing disease recurrence in early-stage lung cancer.
• NCT05690945: This is a strategically critical, randomized, double-blind, active-controlled study in the first-line setting for advanced or metastatic NSCLC patients whose tumors are PD-L1 negative (TPS < 1%).[10] This patient population derives limited benefit from current PD-1 inhibitor-based therapies and represents a high unmet need. The trial is designed as a head-to-head comparison of QL1706 plus chemotherapy versus the approved PD-1 inhibitor tislelizumab plus chemotherapy. A positive outcome in this study would provide definitive evidence of QL1706's superiority over standard anti-PD-1 therapy in this challenging population, which would be a transformative result.

Cervical Cancer

Cervical cancer is the indication for which QL1706 achieved its first regulatory approval, based on a sequence of studies demonstrating its activity in patients with advanced disease.

• Phase Ib Study (NCT05171790): The initial signal of efficacy in cervical cancer came from a cohort within this broader Phase 1b study. In heavily pre-treated patients with recurrent and/or metastatic cervical cancer, QL1706 monotherapy demonstrated promising and durable clinical activity.[18] Among patients who were immunotherapy-naïve, the ORR was a clinically meaningful 28.3%.[2]
• Phase II Monotherapy Study (NCT05557565 / DUBHE-C-206): This single-arm, multicenter Phase II trial was pivotal for the drug's approval. The study enrolled 148 patients with recurrent or metastatic cervical cancer who had failed at least one prior line of platinum-based therapy. Treatment with QL1706 monotherapy (5.0 mg/kg Q3W) resulted in an Independent Review Committee (IRC)-assessed ORR of 33.8% (95% CI: 26.2%-42.0%) and a DCR of 64.9%. The mPFS was 5.4 months, and the 12-month overall survival rate was 65.4%.[40] Importantly, the drug showed activity regardless of PD-L1 expression status, with an ORR of 25.6% in patients with a Combined Positive Score (CPS) of <1.[41] These robust results in a refractory population led to the accelerated approval by the NMPA.
• Phase II First-Line Combination Study: To explore its potential earlier in the treatment paradigm, a separate Phase II study evaluated QL1706 in combination with chemotherapy (paclitaxel and platinum), with or without bevacizumab, as a first-line treatment for recurrent or metastatic cervical cancer. The results, presented at the ESMO Congress 2023, were striking. In 58 evaluable patients, the combination yielded an ORR of 81.0% and a DCR of 98.3%. The mPFS reached 14.3 months, a substantial improvement over historical standards.[42] These data provide strong support for the ongoing randomized Phase III trial (NCT05446883), which aims to confirm these findings and establish this regimen as a new first-line standard of care.[13]

Hepatocellular Carcinoma (HCC)

The development of QL1706 in advanced hepatocellular carcinoma (aHCC) is notable for its scientifically rigorous trial design, which has provided direct clinical validation of the dual-target approach.

• Phase Ib/II Randomized Study (NCT05603039): This study was designed to isolate and quantify the therapeutic contribution of the anti-CTLA-4 component of QL1706. In the randomized portion of the trial, treatment-naïve patients with aHCC received either QL1706 plus bevacizumab or QL1604 plus bevacizumab. QL1604 is a standalone anti-PD-1 monoclonal antibody that has the same protein sequence as the Tuvonralimab component of QL1706.[45] This design created a near-perfect control arm, where the only significant difference between the two groups was the presence of the Iparomlimab (anti-CTLA-4) antibody. The results were compelling: the QL1706 arm achieved an ORR of 38.3% and an mPFS of 6.7 months, which was numerically superior to the QL1604 arm's ORR of 15.4% and mPFS of 5.4 months.[45] This more than doubling of the response rate provides strong clinical evidence that the anti-CTLA-4 component is highly active and drives a significant portion of the combination's efficacy, validating the fundamental rationale for the MabPair product.

Other Investigated Solid Tumors

The broad clinical development program for QL1706 extends to several other solid tumors, with multiple early- and late-stage trials underway.

• Nasopharyngeal Carcinoma (NPC): Data from the Phase 1/1b study showed a promising ORR of 24.5% in a cohort of 110 patients with advanced NPC, a population that was heavily pre-treated. In the subset of patients who were immunotherapy-naïve, the ORR was an even more impressive 38.7%.[2] These encouraging results have prompted the initiation of a Phase III trial (NCT06749899) evaluating QL1706 in combination with chemoradiotherapy for high-risk, locoregionally-advanced NPC.[46]
• Breast Cancer: QL1706 is being actively investigated in breast cancer, particularly in triple-negative breast cancer (TNBC), an aggressive subtype with limited treatment options. Several Phase II trials are exploring its use in different settings: NCT06786026 is evaluating QL1706 plus nab-paclitaxel with or without bevacizumab in the first-line metastatic setting [47]; NCT07005583 is testing its combination with the PARP inhibitor olaparib for patients with HRD-positive TNBC [48]; and NCT06967103 is investigating its role in the neoadjuvant (pre-surgical) setting for HR+/HER2- breast cancer.[49]
• Gastrointestinal and Gynecological Cancers: The program is expanding into other tumor types with active trials recruiting patients in perioperative gastric cancer (NCT06766305) [50] and advanced endometrial cancer after progression on prior PD-1/L1 inhibitors (NCT06917092).[51] A large, randomized Phase III study (NCT07025239) is also planned to evaluate QL1706 in combination with bevacizumab and chemotherapy for the first-line treatment of metastatic colorectal cancer (mCRC).[9]

Consolidated Safety and Tolerability Profile

A key element of the QL1706 value proposition is its potential for an improved safety profile compared to traditional dual checkpoint inhibitor combinations. The clinical data generated to date provide substantial support for this hypothesis.

The largest safety dataset comes from the first-in-human Phase 1/1b study, which enrolled 518 patients with various advanced solid tumors who received QL1706 monotherapy.[2] In this large population, the treatment was generally well-tolerated. The most frequently reported treatment-related adverse events (TRAEs) were low-grade and manageable, including rash (19.7%), hypothyroidism (13.5%), and pruritus (13.3%).[2] Critically, the incidence of severe (Grade ≥3) TRAEs was 16.0%, and the rate of severe immune-related adverse events (irAEs)—the toxicities of greatest concern with checkpoint inhibitors—was only 8.1%.[2] This rate of severe irAEs appears notably lower than historical rates reported for the combination of nivolumab and ipilimumab, suggesting that the engineered shorter half-life of the anti-CTLA-4 component is successfully mitigating toxicity.

When QL1706 is combined with chemotherapy, the overall incidence and severity of adverse events increase, as expected. In the Phase II NSCLC study, Grade ≥3 TRAEs occurred in 33.0% of patients.[30] In the first-line cervical cancer combination study, where patients received an intensive chemotherapy backbone, Grade ≥3 TRAEs were observed in 83.3% of patients, with the most common events being hematologic toxicities (e.g., decreased white blood cell and neutrophil counts) that are characteristic of the chemotherapy agents used.[43] However, even in these combination settings, the profile of immune-mediated toxicities has remained manageable. The overall safety data across the program supports the conclusion that QL1706 offers a favorable and manageable safety profile, validating its core design principle.

Table 2: Summary of Treatment-Related Adverse Events (TRAEs) Across Key QL1706 Studies

Study (Indication)	N	Any Grade TRAE (%)	Grade ≥3 TRAE (%)	Grade ≥3 irAE (%)	Most Common TRAEs (>10%)	Source Snippet(s)
Phase I/Ib (Solid Tumors, Monotherapy)	518	~66% (in initial 47 pts)	16.0%	8.1%	Rash (19.7%), Hypothyroidism (13.5%), Pruritus (13.3%)	2
Phase II (NSCLC, Combo Therapy)	91	>65%	33.0%	Not specified	Decreased appetite (65.9%), Anemia (65.9%), Infusion reactions (52.7%), Pruritus (48.4%)	30
Phase II (Cervical Cancer, 1L Combo)	60	100%	83.3%	Not specified	WBC decrease (71.3%), Neutrophil decrease (68.3%), Anemia (43.3%)	43
Phase II (Cervical Cancer, >2L Mono)	148	70.3%	24.3%	Not specified	Hypothyroidism (20.9%), Hyperthyroidism (18.9%)	40

Pharmacokinetics, Pharmacodynamics, and Dosing Regimen

The clinical development of QL1706 included a rigorous Phase 1 program to define its pharmacokinetic (PK) and pharmacodynamic (PD) properties, establish its safety and tolerability, and determine the optimal dose for subsequent studies. This process was essential for validating the drug's novel design and ensuring a data-driven approach to its late-stage development.

Dose Escalation and Recommended Phase 2 Dose (RP2D)

The first-in-human trial (NCT04296994) was a dose-escalation and expansion study that enrolled patients with a range of advanced solid tumors who had failed standard therapies.[2] The dose-escalation portion followed an accelerated 3+3 design, a standard methodology in early-phase oncology trials. Patients received QL1706 as an intravenous infusion once every 3 weeks (Q3W), with cohorts evaluating doses ranging from 0.3 mg/kg up to 10 mg/kg.[2]

The study successfully identified the Maximum Tolerated Dose (MTD). At the 10 mg/kg dose level, two of the six patients treated experienced dose-limiting toxicities (DLTs): one patient had Grade 3 thrombocytopenia (low platelet count) and another had Grade 4 immune-mediated nephritis (severe kidney inflammation).[2] The occurrence of DLTs in one-third of the patients at this level established 10 mg/kg as the MTD.

Based on a comprehensive analysis that integrated all available data on safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity, the Recommended Phase 2 Dose (RP2D) was established at 5 mg/kg Q3W.[2] The selection of an RP2D that is half of the MTD reflects a thoughtful and mature development strategy. It indicates that the developers prioritized finding an optimal therapeutic window—the dose that maximizes the efficacy-to-toxicity ratio—rather than simply advancing the highest dose that was tolerated. This data-driven decision provides confidence that the 5 mg/kg dose used in the subsequent Phase II and III trials is well-justified and optimized for clinical benefit.

Validated Pharmacokinetic Profile

A primary goal of the early-phase studies was to confirm in humans that the molecular engineering of QL1706 translated to the intended differential pharmacokinetic profile. The clinical PK data successfully validated the preclinical design. As intended, the analysis confirmed that the anti-CTLA-4 antibody component (Iparomlimab) had a faster clearance rate and a shorter elimination half-life (t1/2​ of 4–5 days) compared to the anti-PD-1 antibody component (Tuvonralimab), which exhibited a longer half-life (t1/2​ of 6–9 days).[20]

This confirmed differential PK profile is a critical feature of the drug. It results in a significantly lower overall systemic exposure to the anti-CTLA-4 antibody over the course of the 3-week dosing interval compared to the anti-PD-1 antibody. This pharmacokinetic behavior is the mechanistic basis for the drug's favorable safety profile, as it is believed to reduce the risk of cumulative, exposure-dependent immune-related toxicities that are primarily driven by sustained CTLA-4 blockade.[20] The successful clinical validation of this unique PK profile is a key achievement of the development program.

Regulatory Landscape and Approval Status

The regulatory journey of QL1706 reflects a "China First" global development strategy, leveraging the strengths of its domestic market to achieve a first-in-world approval while simultaneously progressing through the regulatory pathways in other major jurisdictions.

China: National Medical Products Administration (NMPA)

QL1706 has achieved its most significant regulatory milestone in China. On October 16, 2024, Sound Biologics announced that its partner, Qilu Pharmaceutical, had received accelerated approval for PSB205/QL1706 from China's National Medical Products Administration (NMPA).[33] The approval is for the treatment of patients with recurrent or metastatic cervical cancer who have progressed on or after first-line standard therapy. This landmark decision marks the first-ever regulatory approval for a product based on the novel MabPair technology platform anywhere in the world.[34] Another source indicates a potential NMPA approval date of November 21, 2024.[53] This rapid approval underscores the strength of the clinical data from the DUBHE-C-206 (NCT05557565) trial and addresses a significant unmet medical need in this patient population.

United States: Food and Drug Administration (FDA)

The regulatory process in the United States began on April 10, 2019, when the FDA allowed the Investigational New Drug (IND) application for PSB205.[33] This authorization permitted the initiation of clinical trials in the U.S., including the Phase 1 study NCT03986606.[14] To date, there is no public information available to suggest that a Biologics License Application (BLA) has been submitted to or approved by the FDA for any indication.[34] The global development strategy appears prioritized on securing approval in China first, likely to be followed by submissions in Western markets pending the outcomes of the ongoing global Phase III trials.

Europe: European Medicines Agency (EMA)

The provided research materials contain no information regarding any submissions, such as a Marketing Authorisation Application (MAA), to the European Medicines Agency (EMA).[56] Similar to the U.S. strategy, engagement with the EMA is likely planned for a later stage, contingent upon the maturation of the late-stage clinical trial data.

The "China First" approach is a logical strategy for Qilu Pharmaceutical. It allows the company to navigate a familiar regulatory environment, leverage its extensive clinical trial network within China, and potentially generate early revenue and real-world evidence in a large domestic market. This success in China provides a strong foundation and validation for subsequent regulatory submissions in the United States and Europe.

Competitive Analysis and Future Perspectives

QL1706 is entering a dynamic and highly competitive cancer immunotherapy market. Its success will depend not only on its intrinsic clinical merits but also on its ability to differentiate itself from a range of existing and emerging therapies. The future outlook for QL1706 is promising but hinges on the successful execution and positive readouts of its extensive late-stage clinical program.

Competitive Landscape

The competitive environment for QL1706 can be analyzed in two tiers: direct competitors employing a dual PD-1/CTLA-4 blockade strategy, and broader competitors within specific cancer indications.

• Direct Competitors (Dual Blockade): The primary benchmark for dual checkpoint inhibition is the combination of nivolumab (Opdivo®, anti-PD-1) and ipilimumab (Yervoy®, anti-CTLA-4). This combination is approved for multiple indications and has established the efficacy of the dual-blockade concept, but its use is often limited by a high rate of severe immune-related adverse events.[22] Another direct competitor, particularly in the Chinese market, is cadonilimab, a single-molecule bispecific antibody targeting both PD-1 and CTLA-4, which was the first of its kind to receive regulatory approval.[26] QL1706 must demonstrate a superior or non-inferior profile to these agents.
• Broader Competitors (Indication-Specific): In each specific tumor type, QL1706 will compete with the established standard of care. In NSCLC, this includes PD-1/PD-L1 inhibitors like pembrolizumab, nivolumab, and atezolizumab, used either as monotherapy or in combination with chemotherapy.[28] In cervical cancer, the standard of care also includes pembrolizumab plus chemotherapy, with or without bevacizumab, for PD-L1-positive disease.[59] QL1706-based regimens must demonstrate a clear clinical benefit over these entrenched therapies to gain market share.

Potential Competitive Advantages

QL1706's strategy for differentiation is built on a foundation of innovative bioengineering, aiming to deliver tangible clinical advantages.

1. Potentially Superior Safety and Tolerability: This is the cornerstone of QL1706's value proposition. The engineered shorter half-life of its anti-CTLA-4 component is designed to provide a more favorable safety profile, particularly a lower incidence of severe irAEs, compared to the nivolumab/ipilimumab combination. The clinical data to date, showing a Grade ≥3 irAE rate of only 8.1% in a large monotherapy cohort, strongly supports this potential advantage.[2] A demonstrably better safety profile could make dual checkpoint blockade accessible to a broader patient population, including those who are older or have comorbidities.
2. High Efficacy, Especially in First-Line Settings: The clinical data have consistently shown high objective response rates when QL1706 is combined with chemotherapy and/or bevacizumab in the first-line treatment of NSCLC (~60%) and cervical cancer (~81%).[6] If these results are confirmed in Phase III trials, they could establish QL1706 as a best-in-class first-line option.
3. Administrative Convenience: As a single, co-formulated product, QL1706 offers significant logistical advantages over combinations that require the preparation and administration of two separate intravenous drugs. This can reduce pharmacy time, nursing time, and the potential for administrative errors, making it a more efficient option for healthcare systems.

Future Perspectives and Critical Milestones

The future trajectory of QL1706 is intrinsically linked to the outcomes of its ongoing Phase III clinical trials.[38] Several of these studies are particularly critical for defining its role in major oncology markets.

The Phase III trial NCT05690945 is of paramount strategic importance. This study is not only a head-to-head comparison against an active standard of care (tislelizumab plus chemotherapy), but it is also being conducted in the PD-L1-negative NSCLC population—a group with a high unmet medical need where standard PD-1 inhibitors have shown limited benefit.[17] A positive result in this trial would be a landmark achievement, unequivocally demonstrating the superiority of the dual-blockade approach of QL1706 over standard single-pathway inhibition in a commercially and clinically significant patient segment.

Similarly, the successful completion of the Phase III first-line cervical cancer trial (NCT05446883) could expand upon its current approval in the refractory setting and establish QL1706 as the foundational immunotherapy for this disease. The broad scope of the development program, with late-stage trials in NSCLC, cervical cancer, NPC, and mCRC, indicates a clear ambition to position QL1706 as a versatile, cornerstone immuno-oncology agent applicable to a wide range of solid tumors. The continued exploration of novel combinations, such as with PARP inhibitors in breast cancer, further highlights the potential for future growth and label expansion.

Conclusion and Strategic Recommendations

QL1706 (Iparomlimab/Tuvonralimab) represents a scientifically sophisticated and clinically promising advancement in the field of dual immune checkpoint inhibition. Its development is centered on a compelling hypothesis: that by intelligently engineering the pharmacokinetic properties of the anti-CTLA-4 component, it is possible to retain the potent synergistic efficacy of dual PD-1/CTLA-4 blockade while significantly improving upon the challenging safety profile that has limited first-generation combinations. The proprietary MabPair platform provides an elegant and practical solution for delivering this engineered combination as a single, convenient therapeutic product.

The extensive clinical data generated to date, culminating in an accelerated approval in China for cervical cancer, provide strong validation for this approach. The drug has demonstrated high response rates, particularly in first-line combination settings across multiple tumor types, and the large-scale safety data from monotherapy trials support the assertion of a favorable and manageable tolerability profile. The randomized trial in hepatocellular carcinoma has provided direct clinical proof of the anti-CTLA-4 component's essential contribution to efficacy, confirming that QL1706 is a true dual-action agent.

SWOT Analysis

• Strengths:
• Innovative Mechanism: A novel MabPair platform with a strong, data-supported scientific rationale for an improved therapeutic index.
• Compelling Clinical Efficacy: Demonstrated high objective response rates and durable benefits in multiple solid tumors, especially in first-line combination regimens.
• Favorable Safety Profile: A large clinical dataset suggests a lower incidence of severe immune-related adverse events compared to historical data for conventional dual checkpoint blockade.
• Administrative Convenience: A single-product formulation simplifies pharmacy preparation and patient administration.
• Regulatory Validation: Has achieved its first marketing approval from a major regulatory agency (NMPA).
• Weaknesses:
• Limited Phase III Data: While Phase II results are strong, the program's success ultimately depends on randomized, controlled Phase III data, which is not yet mature.
• Geographically Focused Development: The clinical program has been heavily concentrated in China, which may require additional bridging studies or data to fully satisfy Western regulatory agencies and convince global key opinion leaders.
• Uncertainty in Head-to-Head Settings: The outcome of direct comparisons against active standards of care, such as in the NCT05690945 NSCLC trial, remains a key unknown.
• Opportunities:
• Best-in-Class Potential: If Phase III trials confirm both superior efficacy and safety, QL1706 could become the preferred agent for dual checkpoint inhibition.
• Addressing Unmet Needs: Strong potential in difficult-to-treat populations, such as PD-L1-negative NSCLC and TKI-resistant EGFR-mutant NSCLC.
• Broad Pipeline Potential: The platform's applicability across numerous solid tumors creates a "pipeline in a product," with significant opportunities for label expansion.
• Threats:
• Intense Market Competition: The immuno-oncology market is crowded and dominated by established players with blockbuster drugs. Gaining market share will be challenging.
• Pivotal Trial Risk: Failure to meet primary endpoints in key Phase III trials would significantly curtail its clinical and commercial potential.
• Evolving Treatment Paradigms: The rapid pace of innovation in oncology means that new therapeutic modalities (e.g., novel ADCs, cell therapies) could emerge as competitors.

Strategic Recommendations

For stakeholders, including investors, clinical development strategists, and potential partners, QL1706 should be viewed as a high-potential, strategically de-risked asset with transformative potential. The following recommendations are proposed:

1. Prioritize Monitoring of Pivotal Phase III Readouts: The most critical near-term catalysts are the data readouts from the ongoing Phase III trials. Particular attention should be paid to NCT05690945 (first-line PD-L1 negative NSCLC) and NCT05446883 (first-line cervical cancer). The results of these trials will be the ultimate arbiters of the drug's value and its position in the global treatment landscape.
2. Focus on the Differentiated Safety Profile: The favorable safety profile is the drug's most significant competitive advantage. Future publications and regulatory submissions should continue to emphasize the low rate of severe irAEs and the manageable nature of toxicities, as this will be a key driver of physician adoption, particularly in less-fit patient populations.
3. Plan for Global Expansion: While the "China First" strategy has been successful, a clear roadmap for regulatory engagement and clinical development in the U.S. and Europe is necessary. This should include generating data in more diverse, global patient populations to ensure broad applicability and acceptance.
4. Explore Novel Combination Strategies: The promising activity seen in combination with chemotherapy and anti-angiogenics should be expanded. The ongoing trial with a PARP inhibitor is a good example. Further investigation into combinations with antibody-drug conjugates (ADCs), targeted therapies, and other immunomodulatory agents could unlock new areas of synergy and further expand the drug's utility.

In conclusion, QL1706 is a well-designed, innovative immunotherapy that has successfully translated a sophisticated bioengineering concept into compelling clinical results. Its future as a cornerstone of cancer therapy will be determined by its performance in the crucible of Phase III trials, but the evidence to date positions it as one of the most promising next-generation immuno-oncology assets in late-stage development.

Works cited

1. QL1706 Unknown Status Phase 2 Trials for Cervical Cancer Treatment | DrugBank Online, accessed August 19, 2025, https://go.drugbank.com/drugs/DB17562/clinical_trials?conditions=DBCOND0028450&phase=2&purpose=treatment&status=unknown_status
2. First-in-human phase I/Ib study of QL1706 (PSB205), a bifunctional PD1/CTLA4 dual blocker, in patients with advanced solid tumors - PubMed, accessed August 19, 2025, https://pubmed.ncbi.nlm.nih.gov/37158938/
3. Iparomlimab and tuvonralimab (QL1706) plus chemotherapy and bevacizumab for EGFR-mutant patients with advanced non-small cell lung cancer after failure of EGFR-tyrosine kinase inhibitors: updated results from cohort 5 in the DUBHE-L-201 study - PubMed, accessed August 19, 2025, https://pubmed.ncbi.nlm.nih.gov/40713827/
4. Iparomlimab/Tuvonralimab - Drug Targets, Indications, Patents - Patsnap Synapse, accessed August 19, 2025, https://synapse.patsnap.com/drug/c8faaee31e7b4782aeeffebe411d9624
5. Non-Small Cell Lung Cancer Pipeline Outlook Report 2025: Key 100+ Companies And Breakthrough Therapies Shaping The Future Landscape - Barchart.com, accessed August 19, 2025, https://www.barchart.com/story/news/34058143/nonsmall-cell-lung-cancer-pipeline-outlook-report-2025-key-100-companies-and-breakthrough-therapies-shaping-the-future-landscape
6. Qilu Pharmaceutical Releases Latest Results of QL1706 plus Chemotherapy +/- Bevacizumab for the Treatment of Non-Small Cell Lung Cancer in the Phase II Study at ESMO Asia Congress 2022 - BioSpace, accessed August 19, 2025, https://www.biospace.com/qilu-pharmaceutical-releases-latest-results-of-ql1706-plus-chemotherapy-bevacizumab-for-the-treatment-of-non-small-cell-lung-cancer-in-the-phase-ii-study-at-esmo-asia-congress-2022
7. Qilu Pharmaceutical Announces Progress of Clinical Study of QL1706, an Innovative Bifunctional Antibody - PR Newswire, accessed August 19, 2025, https://www.prnewswire.com/news-releases/qilu-pharmaceutical-announces-progress-of-clinical-study-of-ql1706-an-innovative-bifunctional-antibody-301710896.html
8. A Study of QL1706 Combined With Platinum-containing Chemotherapy in Adjuvant Treatment of Stage II-IIIB Non-small Cell Lung Cancer After Complete Surgical Resection. | ClinicalTrials.gov, accessed August 19, 2025, https://www.clinicaltrials.gov/study/NCT05487391
9. Study Details | QL1706 Injection Plus Bevacizumab and XELOX vs Placebo Plus Bevacizumab and XELOX as First-Line Treatment of Unresectable Metastatic Colorectal Cancer | ClinicalTrials.gov, accessed August 19, 2025, https://clinicaltrials.gov/study/NCT07025239
10. A Study of QL1706 in Combination With Chemotherapy in PD-L1-Negative Non-small Cell Lung Cancer | ClinicalTrials.gov, accessed August 19, 2025, https://www.clinicaltrials.gov/study/NCT05690945
11. Study Details | A Phase II Trial to Evaluate the Efficacy and Safety of QL1706 in Patients With Cervical Cancer | ClinicalTrials.gov, accessed August 19, 2025, https://www.clinicaltrials.gov/study/NCT05557565
12. A Phase II Trial to Evaluate the Efficacy and ... - ClinicalTrials.gov, accessed August 19, 2025, https://clinicaltrials.gov/study/NCT05557565
13. QL1706 Plus Chemotherapy±Bevacizumab for the First-Line Treatment of Persistent, Recurrent or Metastatic Cervical Cancer | ClinicalTrials.gov, accessed August 19, 2025, https://clinicaltrials.gov/study/NCT05446883
14. PSB205 - Sound Biologics, accessed August 19, 2025, https://www.soundbiologics.com/pipeline/psb205/
15. First-in-human phase I/Ib study of QL1706 (PSB205), a bifunctional PD1/CTLA4 dual blocker, in patients with advanced solid tumors - PubMed Central, accessed August 19, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10169367/
16. QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk TNBC Breast Cancer - CareAcross, accessed August 19, 2025, https://www.careacross.com/clinical-trials/trial/NCT06404736
17. A phase III, multicenter, double-blinded, randomized, active ... - ASCO, accessed August 19, 2025, https://www.asco.org/abstracts-presentations/ABSTRACT410180
18. Efficacy and safety of QL1706, a novel dual immune checkpoint blockade containing a mixture of anti-PD1 IgG4 and anti-CTLA4 IgG1 antibodies, for advanced cervical cancer: Cohort data from a phase 1b trial. - ASCO Publications, accessed August 19, 2025, https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.5535
19. Abstract CT119: Development and preliminary clinical activity of QL1706 (PSB205), a combination of anti-PD1 and anti-CTLA-4 antibodies manufactured together as a single product - AACR Journals, accessed August 19, 2025, https://aacrjournals.org/cancerres/article/81/13_Supplement/CT119/669716/Abstract-CT119-Development-and-preliminary
20. Abstract CT119: Development and preliminary clinical activity of QL1706 (PSB205), a combination of anti-PD1 and anti-CTLA-4 antibodies manufactured together as a single product | Request PDF - ResearchGate, accessed August 19, 2025, https://www.researchgate.net/publication/352921938_Abstract_CT119_Development_and_preliminary_clinical_activity_of_QL1706_PSB205_a_combination_of_anti-PD1_and_anti-CTLA-4_antibodies_manufactured_together_as_a_single_product
21. Safety of dual checkpoint-blockade with PSB205, an anti-PD-1/CTLA4 monoclonal antibody combination, manufactured and dispensed as a single product: A phase 1 study. - ASCO Meeting Program Guide, accessed August 19, 2025, https://meetings.asco.org/abstracts-presentations/209928
22. First-in-human phase I/Ib study of QL1706 (PSB205), a bifunctional PD1/CTLA4 dual blocker, in patients with advanced solid tumors - ResearchGate, accessed August 19, 2025, https://www.researchgate.net/publication/370605856_First-in-human_phase_IIb_study_of_QL1706_PSB205_a_bifunctional_PD1CTLA4_dual_blocker_in_patients_with_advanced_solid_tumors
23. Non-Small-Cell Lung Cancer (NSCLC) Pipeline Landscape Report 2024: Comprehensive Insights About 100+ Companies and 120+ Pipeline Drugs - ResearchAndMarkets.com - Business Wire, accessed August 19, 2025, https://www.businesswire.com/news/home/20240306736764/en/Non-Small-Cell-Lung-Cancer-NSCLC-Pipeline-Landscape-Report-2024-Comprehensive-Insights-About-100-Companies-and-120-Pipeline-Drugs---ResearchAndMarkets.com
24. Qilu Pharmaceutical Announces Progress of Clinical Study of QL1706, an Innovative Bifunctional Antibody - BioSpace, accessed August 19, 2025, https://www.biospace.com/qilu-pharmaceutical-announces-progress-of-clinical-study-of-ql1706-an-innovative-bifunctional-antibody
25. What is QL 1706 used for? - Patsnap Synapse, accessed August 19, 2025, https://synapse.patsnap.com/article/what-is-ql-1706-used-for
26. Bispecific antibodies targeting immunomodulatory checkpoints for cancer therapy - PMC, accessed August 19, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10038071/
27. Design and Efficacy of a Monovalent Bispecific PD-1/CTLA4 Antibody That Enhances CTLA4 Blockade on PD-1+ Activated T Cells | Cancer Discovery - AACR Journals, accessed August 19, 2025, https://aacrjournals.org/cancerdiscovery/article/11/5/1100/666290/Design-and-Efficacy-of-a-Monovalent-Bispecific-PD
28. Immunotherapy for Non-Small Cell Lung Cancer | Immune Checkpoint Inhibitors, accessed August 19, 2025, https://www.cancer.org/cancer/types/lung-cancer/treating-non-small-cell/immunotherapy.html
29. Advancing non-small cell lung cancer treatment: the power of combination immunotherapies, accessed August 19, 2025, https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1349502/full
30. QL1706 (anti-PD-1 IgG4/CTLA-4 antibody) plus chemotherapy with or without bevacizumab in advanced non-small cell lung cancer: a multi-cohort, phase II study - PMC, accessed August 19, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10822847/
31. A Multiple Tumor Species, Open and Multi-center Clinical Study of Alpaloritovorelli Antibodies (QL-1706) Combined with Pulsed Low Dose Rate External Irradiation (PLDR) for Disease Progression After Previous Anti-tumor Therapy | ClinicalTrials.gov, accessed August 19, 2025, https://clinicaltrials.gov/study/NCT06760676
32. Advances of Qilu Pharmaceutical's QL1706 in Clinical Research Presented at ASCO Annual Meeting APAC - PR Newswire, accessed August 19, 2025, https://www.prnewswire.com/apac/news-releases/advances-of-qilu-pharmaceuticals-ql1706-in-clinical-research-presented-at-asco-annual-meeting-301838983.html
33. PRESS RELEASES - Sound Biologics, accessed August 19, 2025, https://www.soundbiologics.com/news/press-releases/
34. Iparomlimab, Tuvonralimab Approved Mixture of 2 - The Antibody Society, accessed August 19, 2025, https://db.antibodysociety.org/db0/1732/
35. QL1706 (anti-PD-1 IgG4/CTLA-4 antibody) plus chemotherapy with or without bevacizumab in advanced non-small cell lung cancer: a multi-cohort, phase II study - PubMed, accessed August 19, 2025, https://pubmed.ncbi.nlm.nih.gov/38282003/
36. Phase II Trial of QL1706 for Advanced NSCLC in Signal Transduction and Targeted Therapy, accessed August 19, 2025, https://synapse.patsnap.com/article/phase-ii-trial-of-ql1706-for-advanced-nsclc-in-signal-transduction-and-targeted-therapy
37. (PDF) QL1706 (anti-PD-1 IgG4/CTLA-4 antibody) plus chemotherapy with or without bevacizumab in advanced non-small cell lung cancer: a multi-cohort, phase II study - ResearchGate, accessed August 19, 2025, https://www.researchgate.net/publication/377775053_QL1706_anti-PD-1_IgG4CTLA-4_antibody_plus_chemotherapy_with_or_without_bevacizumab_in_advanced_non-small_cell_lung_cancer_a_multi-cohort_phase_II_study
38. Qilu Pharmaceutical Releases Latest Results of QL1706 plus Chemotherapy +/- Bevacizumab for the Treatment of Non-Small Cell Lung Cancer in the Phase II Study at ESMO Asia Congress 2022, accessed August 19, 2025, https://firstwordpharma.com/story/5682264
39. Iparomlimab and tuvonralimab (QL1706) plus chemotherapy and ..., accessed August 19, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC12297733/
40. A Phase II Trial to Evaluate the Efficacy and Safety of QL1706 in ..., accessed August 19, 2025, https://clin.larvol.com/trial-detail/NCT05557565
41. Qilu Pharmaceutical Showcases QL1706 Clinical Trial Outcomes in Oral Presentation at ESGO 2024 - PR Newswire, accessed August 19, 2025, https://www.prnewswire.com/news-releases/qilu-pharmaceutical-showcases-ql1706-clinical-trial-outcomes-in-oral-presentation-at-esgo-2024-302090157.html
42. Qilu Pharmaceutical to Showcase Novel Anti-Cancer Drug QL1706 at ESMO Congress 2023 - BioSpace, accessed August 19, 2025, https://www.biospace.com/qilu-pharmaceutical-to-showcase-novel-anti-cancer-drug-ql1706-at-esmo-congress-2023
43. QL1706 in combination with chemotherapy with or without ..., accessed August 19, 2025, https://www.delveinsight.com/esmo-conference-2023/article/Qilu-Pharma-bi-specific-PD-1-CTLA-4-blocker-QL1706
44. QL1706 Recruiting Phase 3 Trials for Metastatic Cervical Cancer Treatment - DrugBank, accessed August 19, 2025, https://go.drugbank.com/drugs/DB17562/clinical_trials?conditions=DBCOND0036674&phase=3&purpose=treatment&status=recruiting
45. An open-label, multicenter, adaptive, phase Ib/II study of QL1706 or QL1604 plus bevacizumab as first-line treatment in patients with advanced hepatocellular carcinoma. | Journal of Clinical Oncology - ASCO Publications, accessed August 19, 2025, https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.4077
46. Study Details | QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma. | ClinicalTrials.gov, accessed August 19, 2025, https://www.clinicaltrials.gov/study/NCT06749899?cond=Nasopharyngeal%20carcinoma%20OR%20%22carcinoma%20of%20nasopharynx%22%20OR%20%22%20carcinoma%20of%20the%20nasopharynx%22%20OR%20%22%20nasopharynx%20carcinoma%22%20OR%20%22%20NPC%22%20OR%20%22%20squamous%20cell%20carcinoma%20of%20the%20nasopharynx%22&aggFilters=status:not%20rec&viewType=Table&rank=9
47. Study Details | QL1706 Plus Chemotherapy +/- Bevacizumab in 1L ..., accessed August 19, 2025, https://clinicaltrials.gov/study/NCT06786026
48. Study Details | Study of 19(T2)28z1xx TRAC-Chimeric Antigen ..., accessed August 19, 2025, https://clinicaltrials.gov/study/NCT07005583
49. Study Details | QL1706 for the Neoadjuvant Treatment of HR+/HER2 ..., accessed August 19, 2025, https://clinicaltrials.gov/study/NCT06967103
50. Gastric Cancers Recruiting Phase 1 Trials for QL1706 (DB17562) | DrugBank Online, accessed August 19, 2025, https://go.drugbank.com/indications/DBCOND0053339/clinical_trials/DB17562?phase=1&status=recruiting
51. Endometrial Adenocarcinomas Recruiting Phase 2 Trials for QL1706 (DB17562) - DrugBank, accessed August 19, 2025, https://go.drugbank.com/indications/DBCOND0066702/clinical_trials/DB17562?phase=2&status=recruiting
52. Sound Biologics - BIO International Convention 2025, accessed August 19, 2025, https://convention.bio.org/exhibitors/sound-biologics
53. YAbS - The Antibody Society, accessed August 19, 2025, https://db.antibodysociety.org/db0/results_therapeutic?sort=dt_appr_us&page=27
54. A Study of PSB205 in Subjects With Advanced Solid Tumors | ClinicalTrials.gov, accessed August 19, 2025, https://clinicaltrials.gov/study/NCT03986606
55. FDA Approval Timeline of Active Immunotherapies | CRI - Cancer Research Institute, accessed August 19, 2025, https://www.cancerresearch.org/regulatory-approval-timeline-of-active-immunotherapies
56. Zirabev | European Medicines Agency (EMA), accessed August 19, 2025, https://www.ema.europa.eu/en/medicines/human/EPAR/zirabev
57. Carvykti | European Medicines Agency (EMA), accessed August 19, 2025, https://www.ema.europa.eu/en/medicines/human/EPAR/carvykti
58. Lung Cancer - Cancer Research Institute, accessed August 19, 2025, https://www.cancerresearch.org/immunotherapy-by-cancer-type/lung-cancer
59. Immunotherapy in cervical cancer: an innovative approach for better treatment outcomes, accessed August 19, 2025, https://www.explorationpub.com/Journals/etat/Article/1002296
60. Cervical Cancer Immunotherapy | Immune Checkpoint Inhibitors, accessed August 19, 2025, https://www.cancer.org/cancer/types/cervical-cancer/treating/immunotherapy.html
61. Non-Small Cell Lung Cancer Pipeline Outlook Report 2025: Key 100+ Companies And Breakthrough Therapies Shaping The Future Landscape - Barchart.com, accessed August 19, 2025, https://www.barchart.com/story/news/34058142/non-small-cell-lung-cancer-pipeline-outlook-report-2025-key-100-companies-and-breakthrough-therapies-shaping-the-future-landscape
62. Cervical Cancers Unknown Status Phase 2 Trials for QL1706 (DB17562) | DrugBank Online, accessed August 19, 2025, https://go.drugbank.com/indications/DBCOND0032507/clinical_trials/DB17562?phase=2&status=unknown_status
63. QL1706 Recruiting Phase 1 Trials for Metastatic Malignant Neoplasm to the Leptomeninges / PD-1 Inhibitors / Pemetrexed Treatment - DrugBank, accessed August 19, 2025, https://go.drugbank.com/drugs/DB17562/clinical_trials?conditions=DBCOND0057483%2CDBCOND0136949%2CDBCOND0111253&phase=1&purpose=treatment&status=recruiting